Current Medical Research and Opinion最新文献

{"title":"A population-based study of incident prescribing for hypercholesterolaemia and hypertension in Scotland: is the healthcare system recovering from the impact of COVID-19?","authors":"Amanj Kurdi, Morven Millar, Uchenna Nnabuko, Stuart McTaggart, Tanja Mueller, Euan Proud, Barry Melia, Marion Bennie","doi":"10.1080/03007995.2025.2482674","DOIUrl":"https://doi.org/10.1080/03007995.2025.2482674","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic caused significant disruptions in healthcare services, with previous studies estimated that the early months of the pandemic led to a substantial decline in new prescriptions for hypercholesterolemia and hypertension. The long-term recovery of healthcare systems in addressing these gaps remains uncertain. We aimed to assess the recovery of the healthcare system in Scotland regarding the initiation of treatments for hypercholesterolemia and hypertension post-COVID-19 pandemic.</p><p><strong>Method: </strong>This retrospective cohort study analysed prescription data from January 2020 to December 2022 in Scotland, as well as In-hours encounters with general practitioners. Incident prescribing patterns for drugs used in the treatment of hypercholesterolemia and hypertension were compared against pre-pandemic averages from 2018-2019. Data were stratified by health regions and socioeconomic status.</p><p><strong>Results: </strong>New treatment initiations for drugs used in the treatment of hypercholesterolemia and hypertension significantly increased from mid-2021 onwards, surpassing pre-pandemic levels. By December 2022, there were approximately 40,000 and 60,000 additional new treatments for drugs used to treat hypercholesterolemia and hypertension, respectively, compared to the expected numbers based on 2018-2019 averages. The stratified analysis showed a relatively higher increase in less deprived quintiles. GP encounter activities mirrored trends in new antihypertensive and lipid-lowering initiations, with a significant reduction starting in March 2020 due to the first COVID-19 lockdown. Encounter rates gradually recovered from May 2020, reaching near pre-pandemic levels by March 2021. Notably, the encounter rate slopes during the reference period (2018-2019) and post-recovery phase (May 2021-December 2022) showed no significant difference [-0.7 (95% CI: -4.0, 2.5) vs. 0.9 (95% CI: -3.1, 4.9)].</p><p><strong>Conclusions: </strong>The observed increase in new treatments for drugs to treat hypercholesterolemia and hypertension suggests recovery of the healthcare system in Scotland following the COVID-19 pandemic. These higher prescribing rates post-pandemic hypothesise potential long-term sequelae associated with COVID-19. The findings demonstrate the potential for improved pharmacotherapy strategies that address both the backlog of untreated cases and new-onset conditions linked to COVID-19. This underscores the need for ongoing surveillance and flexible healthcare responses to manage emerging health challenges effectively. Additionally, our findings suggest novel research areas that could offer a more comprehensive understanding of the COVID-19 pandemic's influence on the prescribing patterns of these widely used medications.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-9"},"PeriodicalIF":2.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling the pandemic: impaired bone metabolism and risk of SARS-CoV-2 infection.","authors":"Emilio Pariente, Marta Martín-Millán, Daniel Nan, Daniel Martínez-Revuelta, Hector Basterrechea, Javier Pardo, Merelyn Bonome, Sandra Solares, Carmen Ramos, Jose-Manuel Olmos-Martinez, Raquel Pascua, Victor M Martínez-Taboada, José Luis Hernández","doi":"10.1080/03007995.2025.2479782","DOIUrl":"10.1080/03007995.2025.2479782","url":null,"abstract":"<p><strong>Introduction: </strong>While the impact of COVID-19 on bone metabolism has been extensively studied, the inverse relationship remains less understood. This study investigates whether impaired bone metabolism is associated with an increased risk of COVID-19 infection.</p><p><strong>Methods: </strong>We conducted a nested case-control study within a population-based cohort, incorporating Kaplan-Meier analysis (KMA) to assess time to infection (TTI) differences. Propensity score matching (1:2) was performed and validated through standardized mean differences (<0.10), variance ratio (=1), and McFadden's pseudo-<i>R</i>² (=0), ensuring balanced covariates. Bone status was evaluated using a composite index (AOMI), which included five components: P1NP and CTX (bone turnover markers), total hip bone mineral density (BMD-TH), trabecular bone score (TBS), and integral volumetric BMD (IvBMD). Inflammation and insulin resistance (IR) were assessed by albumin-to-globulin ratio (AGR <1.50) and the TG/HDL ratio (>2.50 in women and >2.80 in men), respectively.</p><p><strong>Results: </strong>We analysed 294 COVID-19 cases and 528 controls. AOMI+ individuals had a higher prevalence of COVID-19 (41.5% vs. 33.2%; <i>p</i> = 0.031), an adverse lipid pattern (\"A\" profile: high ApoB, LDL and TC) and pronounced bone changes (higher P1NP and CTX, lower BMD-TH, TBS, and IvBMD). AOMI - individuals were more likely to have metabolic syndrome, displayed a different lipid profile (\"B\" profile: elevated TG, AIP, and TG/HDL ratio), fewer bone alterations, and lower COVID-19 prevalence. TG/HDL ratio was 1.66 ± 1 in \"A\" profile, while it was 2.85 ± 1.4 in \"B\" profile individuals (<i>p</i> = 0.0001). Age acted as an effect modifier, and lowest tercile significantly increased COVID-19 risk associated with AOMI+ [Mantel-Haenszel OR = 1.42 (95%CI: 1.08-1.9); <i>p</i> = 0.022]. KMA identified AOMI+ men and individuals of both sexes in lowest age tercile, as groups with shorter TTI: These younger individuals had high CTX (women), low TBS (men), and high ApoB (both). In multivariable analyses, plasma CTX levels negatively correlated with TTI (adjusted β= -0.325; <i>p</i> = 0.0001). AOMI+ status was associated with increased COVID-19 risk after controlling for confounders, including IR (adjusted OR = 1.51; 95%CI: 1.04-2.10; <i>p</i> = 0.027), although this association weakened when adjusting for AGR (95%CI: 0.99-2.28; <i>p</i> = 0.055). ANCOVA-estimated adjusted TBS means were lower in COVID-19 cases compared to controls (1.259 vs. 1.294; <i>p</i> = 0.013).</p><p><strong>Conclusions: </strong>Impaired bone metabolism was found to be associated with increased COVID-19 risk, in a relationship potentially mediated by underlying inflammation. Elevated osteoclastic activity and a defined lipid profile with high ApoB, TC, LDL levels, played a crucial role in the results. Bone quality parameters more accurately captured COVID-19-related bone changes than BMD.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-13"},"PeriodicalIF":2.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traditional Chinese medicine in synergy with conventional therapy improves renal outcomes and provides survival benefit in patients with systemic lupus erythematosus: a cohort study from the largest health care system in Taiwan.","authors":"Chen-Ying Wei, Chiao-Hsuan Chu, Hsuan-Shu Shen, Po-Chuan Ko, Jiun-Liang Chen, Han-Hua Yu","doi":"10.1080/03007995.2025.2478160","DOIUrl":"10.1080/03007995.2025.2478160","url":null,"abstract":"<p><strong>Background: </strong>Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder that significantly impacts renal function. Despite conventional treatments, morbidity and mortality remain high, necessitating the exploration of safer and more effective therapies, including the potential benefits of Traditional Chinese Medicine (TCM) for improving kidney health and survival rates.</p><p><strong>Methods: </strong>Patients with newly diagnosed SLE with catastrophic illness certificate were retrospectively enrolled from the Chang Gung Research Database (CGRD) between 2005 and 2020. Patients were stratified into groups based on TCM treatment post-diagnosis. Outcomes measured included end-stage renal disease (ESRD) incidence and all-cause mortality, using Cox proportional hazard models and Kaplan-Meier analysis for statistical evaluation.</p><p><strong>Results: </strong>Among 10,462 newly diagnosed SLE patients, 1,831 had received at least 28 days of TCM treatment, while 7,966 had not received TCM treatment. After propensity score matching, there were equally 1,831 individuals in each group, with no significant baseline differences in age, sex, biochemical profiles, or comorbidities. TCM usage was associated with a significantly reduced rate of ESRD over a 0.5-year follow-up (adjusted hazard ratio (aHR) = 0.24; 95% confidence interval (CI) = 0.07-0.80, <i>p</i> = .02), with a trend that persisted over 5 years. The TCM group's proteinuria was significantly lower than that of the non-TCM group at various time points post-index date, including 6 months (174.98 mg vs. 248.09 mg, <i>p</i> <.001), 1 year (161.05 mg vs. 303.03 mg, <i>p</i> <.001), 3 years (150.26 mg vs. 250 mg, <i>p</i> = .03), and 10 years (147.06 mg vs. 190.75 mg, <i>p</i> = .03). After adjusting for confounding covariates, TCM users had a significantly decreased risk of mortality (aHR = 0.70, 95% CI = 0.58-0.83).</p><p><strong>Conclusion: </strong>Integrating TCM with conventional treatment could lower risk of ESRD and mortality, highlighting the potential for a more holistic approach to patient care for SLE.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-9"},"PeriodicalIF":2.4,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balanced discussion about bilastine as a truly non-sedating antihistamine.","authors":"Amalia Leceta, Kazuhiro Yanai","doi":"10.1080/03007995.2025.2480190","DOIUrl":"https://doi.org/10.1080/03007995.2025.2480190","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-6"},"PeriodicalIF":2.4,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An international modified Delphi consensus study on the optimal diagnosis and treatment of patients with HFpEF.","authors":"A Sindone, M Abdelhamid, W Almahmeed, J A Figueiredo Neto, A Jordan-Rios, Y Lopatin, H Sümbül, J C Youn, C E Chiang","doi":"10.1080/03007995.2025.2480736","DOIUrl":"https://doi.org/10.1080/03007995.2025.2480736","url":null,"abstract":"<p><strong>Objective: </strong>The global burden of HFpEF is high and, despite developments in available therapies, patient outcomes have not improved significantly. This study aimed to explore the optimal approaches to the diagnosis and treatment of patients with HFpEF and to develop recommendations on how guideline directed medical therapy can be introduced in a more equitable and universal manner.</p><p><strong>Methods: </strong>Using a modified Delphi methodology led by an independent facilitator, a steering group of healthcare practitioners with experience of managing HFpEF identified 41 Likert scale statements across five main domains of focus. This generated an online survey distributed by a third-party provider using a convenience sampling approach to HCPs with experience managing patients with HFpEF.</p><p><strong>Results: </strong>A total of 213 responses were analyzed with 35/41 statements attaining very strong (≥90%) agreement, 4/41 strong (≥75%) agreement, and 2/41 failing to meet the threshold established for consensus (75%). From these results, a total of 8 recommendations to define the optimal approach to diagnosis and treatment of patients with HFpEF are proposed.</p><p><strong>Conclusion: </strong>The burden of HFpEF is set to increase in the future. The high levels of consensus achieved in this study show that there is willingness to implement change and improve patient outcomes for those with this condition. A series of actionable recommendations have been developed based on the levels of agreement attained. It is hoped that the putting the current recommendations into practice will support international efforts to improve HFpEF care.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-17"},"PeriodicalIF":2.4,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantifying the economic impact of premature mortality from cirrhosis in Spain.","authors":"Josep Darbà, Meritxell Ascanio","doi":"10.1080/03007995.2025.2480187","DOIUrl":"https://doi.org/10.1080/03007995.2025.2480187","url":null,"abstract":"<p><strong>Objectives: </strong>Excessive alcohol consumption is a major contributor to illness and mortality on a global scale. Per-capita alcohol consumption rose from 5.5 litres in 2005 to 6.4 litres in 2016 and is projected to reach 7.6 litres by 2030. In 2019, alcohol was associated with roughly a quarter of all cirrhosis-related deaths worldwide. The aim of this study is to assess the economic impact of premature mortality due to cirrhosis in Spain.</p><p><strong>Methods: </strong>To estimate the economic impact of premature mortality due to cirrhosis, we utilized the human capital method. This method involved collecting data on mortality rates, average salaries, and unemployment rates. Our objective was to quantify the financial implications of cirrhosis-related deaths, offering valuable insights for policymakers and healthcare professionals.</p><p><strong>Results: </strong>In 2022, 45% of cirrhosis deaths occurred among individuals of working age. This resulted in the loss of 20,190 years of potential life lost (YPLL), contributing to productivity losses totalling €20.4 billion over a decade. These statistics highlight the significant economic and societal burdens associated with cirrhosis mortality.</p><p><strong>Conclusions: </strong>Over the past two decades, there has been a global increase in alcohol consumption, a trend expected to persist and possibly escalate through 2030. As a direct consequence, projections indicate a corresponding increase in cirrhosis-related deaths over the coming decade. This anticipated rise underscores the ongoing public health challenge posed by alcohol-related liver diseases worldwide.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-17"},"PeriodicalIF":2.4,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Part D Senior Savings Model on racial and ethnic disparities in healthcare costs.","authors":"Chi Chun Steve Tsang, Xiangjun Zhang, Ashley Ellis, Jessie Jiaqi Zeng, Junling Wang","doi":"10.1080/03007995.2025.2479780","DOIUrl":"https://doi.org/10.1080/03007995.2025.2479780","url":null,"abstract":"<p><strong>Objective: </strong>The Centers for Medicare & Medicaid Services tested the Part D Senior Savings Model (\"PDSS Model\") in 2021, capping monthly out-of-pocket (OOP) insulin costs at $35. Diabetes disproportionately affects racial/ethnic minorities compared to their non-Hispanic White (White) counterparts, so this study compared the changes in racial/ethnic disparities in healthcare costs among insulin users between Medicare and non-Medicare populations in 2021.</p><p><strong>Methods: </strong>This study analyzed Medical Expenditure Panel Survey (2020-2021). The intervention group comprised Medicare beneficiaries aged ≥65, while the comparison group included near-elderly non-Medicare population. The study outcomes included annual OOP/total costs in 2021 dollars for insulin, medication, health services (medical), and overall healthcare. A difference-in-differences-in-differences (DDD) approach was employed to assess the PDSS Model's effects between White and each racial/ethnic minority group.</p><p><strong>Results: </strong>The weighted sample included 1,056,386 insulin users (53.89% intervention). In 2020, among the intervention group, non-Hispanic Black (Black) and Hispanic had similar or higher insulin costs than White patients. Black-White differences in OOP insulin costs were lowered more among the intervention group (cost ratio [CR] = 0.12, 95% confidence interval = 0.06-0.22) than the comparison group. Black-White differences in OOP costs for medication, health services, and overall healthcare widened more among the intervention group by 61%-64%. These patterns were not seen for other racial/ethnic disparities.</p><p><strong>Conclusions: </strong>Among insulin users, Black may have benefited more from the PDSS Model than White patients, which may be associated with enhanced insulin access and lower needs for other healthcare. Future studies should examine the long-term and heterogeneous impact of the PDSS Model.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-26"},"PeriodicalIF":2.4,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidities of hypothyroidism.","authors":"Gabriela Brenta, Ulrike Gottwald-Hostalek","doi":"10.1080/03007995.2025.2476075","DOIUrl":"10.1080/03007995.2025.2476075","url":null,"abstract":"<p><p>Hypothyroidism is a relatively common condition that may affect as many as 10% of the population worldwide when its overt and subclinical presentations are considered. Important clinical comorbidities are highly prevalent in people with hypothyroidism and diminish quality of life and functional status in a manner that is proportional to the number of comorbidities present and their severity. This article reviews the common comorbidities of hypothyroidism, as reported in the literature. The comorbidities of hypothyroidism include clinical conditions commonly associated with hypothyroidism, such as dyslipidaemia, hypertension, fatigue or (possibly) cardiovascular disease, and can appear whether or not intervention with LT4 is applied appropriately to ensure biochemical euthyroidism. Other comorbidities may share some pathogenetic background with hypothyroidism, including depression or anxiety, or autoimmune conditions. Hypothyroidism may arise as a comorbidity of some other conditions, e.g. following the application of targeted cancer therapies or some disease-modfying treatments for multiple sclerosis. Other common treatments, including metformin, glucocorticoids or proton pump inhibitors, among others, may alter levels of thyrotropin, thus impacting on the monitoring of thyroid dysfunction and the diagnosis of thyroid dysfunction. Ensuring good control of hypothyroidism is a necessary first step in managing any patient with hypothyroidism. Then, physicians should be aware of the possibility of other comorbid conditions that must be addressed to achieve an optimal patient outcome.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-9"},"PeriodicalIF":2.4,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic burden of myasthenia gravis in China: a nationwide registry-based study.","authors":"Jiazhou Yu, Huanyu Zhang, Shanquan Chen, Dong Dong","doi":"10.1080/03007995.2025.2475075","DOIUrl":"https://doi.org/10.1080/03007995.2025.2475075","url":null,"abstract":"<p><strong>Background: </strong>The long-term treatment of myasthenia gravis (MG) and impaired productivity related to physical decline incur significant economic burdens on affected populations and society. This study aims to evaluate the costs of MG in China from a societal perspective and to identify the cost-driving factors.</p><p><strong>Methods: </strong>A web-based survey was conducted on 1020 MG patients recruited through a national registry system in China. Respondents reported their socio-demographic and disease-related information and annual expenses related to MG under direct medical and non-medical costs. Indirect costs were estimated among 268 working respondents based on hours of missed work and their annual income. Generalized linear models were used to identify factors associated with different categories of costs.</p><p><strong>Results: </strong>Among all respondents, the median annual direct medical cost was US$2219.0, with a median of $1860.2 contributed by medical costs and a median of $248.2 by non-medical costs. Higher education, unemployment, hospitalization, use of mechanical ventilation, and use of multiple medications were significant driving factors of direct medical and non-medical costs. Among respondents who are at least part-time employed, the indirect costs were generally minimal. Older age, physical burden of disease, and use of multiple medications were significant predictors of higher income loss.</p><p><strong>Conclusion: </strong>Population with MG in China reported heavy economic burdens related to medication. Disease severity is a major driving factor of both direct and indirect costs. Targeted policies are needed to alleviate the financial burden of MG on patients and society at large.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-7"},"PeriodicalIF":2.4,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to mt-sDNA testing for colorectal cancer screening among new users in a US Black population.","authors":"Mallik Greene, Shrey Gohil, Mark Camardo, A Burak Ozbay, Paul Limburg, Jerry Lovelace","doi":"10.1080/03007995.2025.2475074","DOIUrl":"10.1080/03007995.2025.2475074","url":null,"abstract":"<p><strong>Objective: </strong>Colorectal cancer (CRC) poses significant mortality risks, particularly among Black individuals, who experience the highest CRC incidence and mortality rates in the United States. This study examined adherence to multi-target stool DNA (mt-sDNA) testing in this population.</p><p><strong>Methods: </strong>This retrospective cohort analysis used Exact Sciences Laboratories (ESL)-linked claims data from January 2017 to December 2023 on Black patients in the United States aged 45 and older. High-risk individuals, those with payers other than commercial plans, managed care organizations, Medicare Advantage, Medicaid, or Medicare, and individuals with mt-sDNA prescriptions outside the study period were excluded. Adherence was defined as the percentage of patients returning the test kit with valid results within 365 days of shipment. Logistic regression analysis was used to identify factors associated with adherence.</p><p><strong>Results: </strong>Among 434,951 patients included in the study, the overall adherence to mt-sDNA testing was 62.0% (<i>N</i> = 266,981), with a mean time to adherence of 27.6 days (SD = 44.17). Females, older adults (76+ years), and non-metropolitan residents had higher adherence than males, younger adults, and metropolitan patients (all <i>p</i> < 0.001), respectively. Patients with orders from GI specialists had higher adherence than other prescribing clinicians (NP/PA: OR = 0.39, OB/GYN: OR = 0.54, Other: OR = 0.38, PCP: OR = 0.50; all <i>p</i> < 0.001). Digital outreach, especially SMS and email combination, was also associated with higher adherence (OR = 1.25, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>This large, national study found a 62.0% adherence rate to mt-sDNA testing among Black individuals. Higher adherence was associated with being female, older age, non-metropolitan residence, and digital outreach. While the findings highlight the promise of mt-sDNA, further research is needed to explore its full potential in improving CRC screening adherence across different demographic groups.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-8"},"PeriodicalIF":2.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}